A New Year for COVID-19 and the Pandemic: Triumphs and Challenges
Dr Ryan Maves, CHEST COVID-19 Task Force Chair, talks about COVID-19-related triumphs of 2021, what clinicians can do now, and challenges for 2022.
COVID19
Longer Time Spent Sitting During the COVID-19 Pandemic Linked With Depressive Symptoms
The aim of this study was to understand the relation between changes in behavior and mental health during the early phase of the first wave of the COVID-19 pandemic in the United States during April and May, 2020.
FDA Warns Against Using LuSys Laboratories COVID-19 Tests
These tests have not been authorized, cleared, or approved by the FDA for distribution or use in the United States.
Oral Antiviral Treatments for COVID-19: Molnupiravir and Paxlovid
Concise drug information for molnupiravir and Paxlovid; the FDA granted Emergency Use to both oral antiviral therapies.
COVID-19 and Moral Injury: a Mental Health Pandemic for Frontline Health Care Workers
Intervention strategies for health care workers experiencing COVID-19-related moral injury include health promotion, resilience training, and ongoing multilevel support.
Children With Cancer Have Greater Risk of Severe COVID-19 Outcomes
About 20% of pediatric cancer patients who developed COVID-19 had severe or critical disease.
How to Prevent COVID-19 Vaccination From Interfering With Cancer Imaging
Education, communication, and coordination are key.
COVID-19 Vaccination Linked to Small Increase in Menstrual Cycle Length
Data from the Natural Cycles app was analyzed for an association between COVID-19 vaccination menstrual cycle changes.
Efficacy, Safety of the Ad5-nCoV Vaccine for Protection Against COVID-19
Researchers conducted a study to determine the safety and efficacy of the Ad5-nCoV vaccine for protection against SARS-CoV-2 infection in adult patients.
FDA Shortens Booster Dose Interval for Moderna COVID-19 Vaccine
The Moderna booster dose is authorized for individuals 18 years of age and older.
- Loading...
Loading...
Next post in News
Loading... 
Loading...